Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 7/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | RBM17 | Q96I25 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508977 | 1.00 | DRD2 (0.47) | DRD2DRD3HTR4ADORA2BPOLB | |
| SCHEMBL19175211 | 0.87 | HTR4 (0.49) | HTR4ADORA2BDRD4GAASUV39H2 | |
| SCHEMBL19175191 | 0.85 | CHRM1 (0.48) | HTR4ADORA2BOPRL1GAA | |
| SCHEMBL6497356 | 0.84 | DRD2 (0.55) | DRD2DRD3OPRM1OPRK1OPRL1 | |
| SCHEMBL311333 | 0.84 | HTR4 (0.44) | HTR4ADORA2BDRD4GAA | |
| SCHEMBL29508898 | 0.83 | MAPT (0.54) | DRD2DRD3POLBDRD4GAA | |
| SCHEMBL22858439 | 0.83 | MAPT (0.54) | DRD2DRD3POLBDRD4GAA | |
| SCHEMBL22858617 | 0.79 | ALDH1A1 (0.46) | DRD2DRD3POLBOPRM1OPRK1 | |
| SCHEMBL29508999 | 0.79 | ALDH1A1 (0.46) | DRD2DRD3POLBOPRM1OPRK1 | |
| SCHEMBL22858591 | 0.77 | HTR3A (0.57) | DRD2DRD3DRD4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | DRD2 4228/4885DRD3 3893/4885HTR4 1684/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | DRD2 4228/4885DRD3 3893/4885HTR4 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.